RecruitingNot ApplicableNCT06275555
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
Efficacy and Safety of Bivalirudin Versus Heparin in Anticoagulant Therapy of ECMO: a Randomized Controlled Trial
Sponsor
Xiaotong Hou
Enrollment
154 participants
Start Date
Jun 3, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Age ≥ 18 years old
- Accept VA-ECMO or VV-ECMO
- the ECMO team believes that systemic anticoagulation is necessary and that APTT should be maintained at 40-60s.
- sign the informed consent form
Exclusion Criteria6
- previous history of allergy to heparin or bivalirudin
- previous diagnosis of heparin-induced thrombocytopenia.
- the pre-random ECMO assistance time is more than 48 hours.
- pregnant female
- have participated in this study before.
- the researchers believe that there are other factors that are not suitable to participate in this study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGbivalirudin
bivalirudin as an anticoagulant
DRUGunfractionated heparin
unfractionated heparin as an anticoagulant
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06275555
Related Trials
Study on the Efficacy and Timing of ECMO Therapy in Children With Refractory Septic Shock
NCT039480481 location
Platform of Randomized Adaptive Clinical Trials in Critical Illness
NCT0544085186 locations
Anticoagulation-free VV ECMO for Acute Respiratory Failure
NCT042736071 location
Transplantation of Autologously Derived Mitochondria Following Ischemia
NCT028517581 location
Continuous Compartment Pressure Monitoring for Compartment Syndrome in VA-ECMO Patients
NCT058307211 location